Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Canadian Cancer Trials Group HE.1: A phase III study of palliative radiotherapy for symptomatic hepatocellular carcinoma and liver metastases.
Presenter
Laura A. Dawson, MD, FASTRO, FRCPC
Princess Margaret Cancer Centre
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Rapid Oral Abstract Session
Session Title
Rapid Abstract Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Clinical Trial Registration Number
NCT02511522
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr LBA492)
DOI
10.1200/JCO.2023.41.4_suppl.LBA492
Abstract #
LBA492
Abstract Disclosures
Similar Videos & Slides
Speaker: Panel Discussion
Videos & Slides
2024 ASCO Annual Meeting
Safety analysis by treatment periods from EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcinoma.
Speaker: Stephen Lam Chan, MD, FRCP, MRCP
Videos & Slides
2024 ASCO Annual Meeting
Phase 2/3 study of livmoniplimab in combination with budigalimab in patients with locally advanced or metastatic hepatocellular carcinoma.
Speaker: Ghassan K. Abou-Alfa, MD, MBA
Videos & Slides
2024 ASCO Gastrointestinal Cancers Symposium
Lenvatinib plus pembrolizumab versus lenvatinib alone as first-line therapy for advanced hepatocellular carcinoma: Longer-term efficacy and safety results from the phase 3 LEAP-002 study.
Speaker: Richard S. Finn, MD